Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Brainstorm Cell (BCLI)

Brainstorm Cell (BCLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
News Movers: Yesterday’s Hottest News That Could Move the Needle Today Stocktwits - Thu Dec 5, 1:38AM CST

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

BCLI : 1.6000 (-0.62%)
LASE : 5.71 (+4.39%)
PPBT : 4.02 (-2.19%)
BCTX : 1.1000 (+1.85%)
STXS : 2.24 (+3.23%)
DMGGF : 0.3300 (+4.83%)
News Movers: Today’s Hottest News That Could Move the Needle Tomorrow wealthyventurecapitalist.com - Mon Dec 2, 7:44PM CST

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

BCLI : 1.6000 (-0.62%)
LASE : 5.71 (+4.39%)
PPBT : 4.02 (-2.19%)
BCTX : 1.1000 (+1.85%)
STXS : 2.24 (+3.23%)
DCTH : 12.27 (+5.23%)
DMGGF : 0.3300 (+4.83%)
BCLI Update - Progress Supports Our 10x Plus Value Range Potential Newswire.ca - Wed Jul 24, 7:30AM CDT

/CNW/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE –...

BCLI : 1.6000 (-0.62%)
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation Newswire.ca - Fri Jun 14, 11:01AM CDT

/CNW/ -- INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the...

BCLI : 1.6000 (-0.62%)
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS PR Newswire - Wed Oct 18, 2023

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 1.6000 (-0.62%)
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI PR Newswire - Sat Oct 7, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BCLI : 1.6000 (-0.62%)
BCLI LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI PR Newswire - Fri Sep 29, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BCLI : 1.6000 (-0.62%)
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 1.6000 (-0.62%)
BrainStorm Cell Therapeutics Stock Trading Halted Today PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 1.6000 (-0.62%)
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

BCLI : 1.6000 (-0.62%)

Barchart Exclusives

These 2 Dividend Stocks Were Stars in November. Is It Too Late to Buy? Barchart - Wed Dec 11, 6:30PM CST
These high-yield dividend stocks have posted great returns in 2024 and could keep heating up in the new year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot